Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07131644 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sirolimus Discontinuation Strategies in Kaposiform Hemangioendothelioma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 4 more changesShow less
    • Trial arms changed: 3 → 2
    • Site details revised
    • Publications: details revised at 5 of 5 entries
    • Eligibility criteria expanded, about 5 words
  2. Start date: Aug 13, 2025 to Sep 13, 2025
    • Secondary endpoints: details revised at 1 of 2 entries
    • Publications: details revised at 5 of 5 entries
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Sirolimus has demonstrated efficacy in the treatment of kaposiform hemangioendothelioma (KHE); however, a high rate of rebound growth following discontinuation has been reported, highlighting the clinical importance of establishing an appropriate withdrawal regimen.
Trial Details
NCT Number NCT07131644
Lead Sponsor West China Hospital
Conditions
(from sponsor)		 Kaposiform Hemangioendothelioma
Related terms Kaposiform Hemangioendothelioma
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov